Australia's MedAdvisor hits 10-1/2-month high on strong Q2 results

Adheris Health

23/01/2023 24:23

** Shares of medication technology co MedAdvisor Ltd
 MDR.AX  climb as much as 21.2% to A$0.315, their highest since
March 7, 2022
    ** Co says Q2 operating revenue up 89.9% at A$44.1 mln 
($30.78 mln), while gross margin rose 164.3% to A$26.4 mln
    ** Says strong qtrly performance due to growing scale in
Australia and the United States, and reflects successful
digitisation strategy
    ** Trading volumes nearly twice the 30-day average of
240,396 shares
    ** MDR flat this year, as of last close, after shedding more
than 34% in 2022
($1 = 1.4327 Australian dollars)
 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))